Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
Public ClinicalTrials.gov record NCT02155647. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma
Study identification
- NCT ID
- NCT02155647
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Enrollment
- 204 participants
Conditions and interventions
Conditions
Interventions
- Avelumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2, 2014
- Primary completion
- May 1, 2019
- Completion
- May 2, 2023
- Last update posted
- Mar 12, 2024
2014 – 2023
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Medical Center | Los Angeles | California | 90024 | — |
| The Angeles Clinic and Research Institute - West LA | Los Angeles | California | 90025 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| H. Lee Moffitt Cancer Center and Research Institute, Inc | Tampa | Florida | 33612 | — |
| National Cancer Institute | Bethesda | Maryland | 20892 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215-5418 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901-1914 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10021 | — |
| Mount Sinai | New York | New York | 10029 | — |
| Peggy & Charles Stephenson Oklahoma Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15213 | — |
| University of Washington - Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02155647, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 12, 2024 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02155647 live on ClinicalTrials.gov.